| 摘要 |
PURPOSE: A pharmaceutical composite formulation containing a platelet aggregation inhibitor and an HMG-CoA reductase inhibitor is provided to improve stability of the platelet aggregation inhibitor and to reduce side effects on a gastrointestinal tract. CONSTITUTION: A pharmaceutical composite formulation comprises an inner layer, an intermediate layer, and an outer layer. The inner layer is prepared by coating an inner core with an enteric polymer. The inner core contains: a platelet aggregation inhibitor or a pharmaceutically acceptable salt thereof; an acidity regulator; and pharmaceutically acceptable additives. The intermediate layer contains water soluble polymers. The outer layer contains an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and the pharmaceutically acceptable additives. The platelet aggregation inhibitor or the pharmaceutically acceptable salt is selected among aspirin, ticlopidine, clopidogrel, cilostazol, and sarpogrelate HCl.
|
